SSO President Calls for Special Training Programs in Surgical Oncology

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

BOSTON--"Our members must stand up as champions of special training in surgical oncology," Society of Surgical Oncology (SSO) president Bernard Gardner, MD, said at the Society's Annual Cancer Symposium. "We must continue to nourish this society because we provide something unique."

BOSTON--"Our members must stand up as champions of specialtraining in surgical oncology," Society of Surgical Oncology(SSO) president Bernard Gardner, MD, said at the Society's AnnualCancer Symposium. "We must continue to nourish this societybecause we provide something unique."

Dr. Gardner is professor of surgery and director of surgical educationat the New Jersey Medical School, Newark.

In an inspirational speech, Dr. Gardner strongly advocated specialtraining programs in surgical oncology. Experienced surgeons specificallytrained to manage cancer-related problems will lead to an improvementin cancer care, he believes. He also called for an increased levelof funding for surgical oncology research as part of trainingprograms. "We must continue to search for new ways to treatcancer," he said.

Dr. Gardner urged surgical oncologists to avoid being intimidatedby the government's efforts to modify aggressive approaches tothe treatment of cancer, and not to allow the government to preventthe early referral of patients with cancer.

The government's attitude does not reflect the complexity of surgicaloperations for cancer, he argued. He also admonished societalattitudes of passivity toward the treatment of cancer, especiallyin the elderly.

Related Videos
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.